A Preclinical Systematic Review of Curcumin for Protecting the Kidney with Ischemia Reperfusion Injury

الملخص EN

Renal ischemia-reperfusion injury (RIRI) refers to a phenomenon associated with dysfunction of the kidney and tissue damage.

Unfortunately, no specific drugs have been found that effectively prevent and treat RIRI.

Curcumin (Cur), a polyphenol extracted from turmeric, possesses a variety of biological activities involving antioxidation, inhibition of apoptosis, inhibition of inflammation, and reduction of lipid peroxidation.

Eight frequently used databases were searched using prespecified search strategies.

The CAMARADES 10-item quality checklist was used to evaluate the risk of bias of included studies, and the RevMan 5.3 software was used to analyze the data.

The risk of bias score of included studies ranged from 3 to 6 with an average score of 5.22.

Compared with the control group, Cur significantly alleviated renal pathology, reduced blood urea nitrogen and serum creatinine levels, and improved inflammatory indexes, oxidant, and apoptosis in RIRI animal models.

Despite the heterogeneity of the response to Cur in terms of serum creatinine, BUN, TNF-alpha, and SOD, its effectiveness for improving the injury of RIRI was remarkable.

In the mouse model subgroup of serum creatinine, the effect size of the method of unilateral renal artery ligation with contralateral nephrectomy and shorter ischemic time showed a greater effect than that of the control group.

No difference was seen in the methods of model establishment, mode administration, or medication times.

The preclinical systematic review provided preliminary evidence that Cur partially improved RIRI in animal models, probably via anti-inflammatory, antioxidant, antiapoptosis, and antifibrosis activities and via improving microperfusion.

ARRIVE guidelines are recommended; blinding and sample size calculation should be focused on in future studies.

These data suggest that Cur is a potential renoprotective candidate for further clinical trials of RIRI.